Table 2 Baseline characters of 488 TCGA-THCA patients

n

381

107

Progression, n (%)

1.000

free

343 (70.3%)

96 (19.7%)

progression

38 (7.8%)

11 (2.3%)

RAS_status, n (%)

1.000

Mutated

46 (9.4%)

13 (2.7%)

Wild type

335 (68.6%)

94 (19.3%)

BRAF_status, n (%)

0.958

Mutated

217 (44.5%)

60 (12.3%)

Wild type

164 (33.6%)

47 (9.6%)

Extrathyroid_extension, n (%)

0.642

Minimal (T3)

102 (21.7%)

28 (5.9%)

Moderate/Advanced (T4)

16 (3.4%)

2 (0.4%)

None

253 (53.7%)

70 (14.9%)

Histological_type, n (%)

0.918

Classical/usual

274 (56.1%)

77 (15.8%)

Follicular

78 (16%)

23 (4.7%)

Tall Cell

29 (5.9%)

7 (1.4%)

Neoplasm_focus_type, n (%)

0.562

Multifocal

167 (34.9%)

51 (10.7%)

Unifocal

206 (43.1%)

54 (11.3%)

Anatomic_site, n (%)

0.861

Bilateral

62 (12.9%)

19 (3.9%)

Isthmus

18 (3.7%)

4 (0.8%)

Unilateral

298 (61.8%)

81 (16.8%)

Residual_tumor, n (%)

0.122

R0

296 (69.5%)

75 (17.6%)

R1

35 (8.2%)

16 (3.8%)

R2

4 (0.9%)

0 (0%)

Ajcc_stage, n (%)

0.083

Stage I

221 (45.5%)

52 (10.7%)

Stage II

34 (7%)

17 (3.5%)

Stage III

82 (16.9%)

28 (5.8%)

Stage IV

43 (8.8%)

9 (1.9%)

M_stage, n (%)

1.000

M0

373 (76.6%)

106 (21.8%)

M1

7 (1.4%)

1 (0.2%)

N_stage, n (%)

0.677

N0

179 (40.9%)

46 (10.5%)

N1

165 (37.7%)

48 (11%)

T_stage, n (%)

0.496

T1

111 (22.8%)

30 (6.2%)

T2

126 (25.9%)

35 (7.2%)

T3

123 (25.3%)

40 (8.2%)

T4

19 (3.9%)

2 (0.4%)

Gender, n (%)

0.620

Female

277 (56.8%)

81 (16.6%)

Male

104 (21.3%)

26 (5.3%)

Age, n (%)

0.860

< 55

255 (52.3%)

70 (14.3%)

≥ 55

126 (25.8%)

37 (7.6%)

Progression_free_interval, meidan (IQR)

938 (491, 1463)

678 (509, 1259)

0.195